Financial News

Recent Quotes
My Watchlist
Indicators
Motherlode Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. (NY: SNY )

43.41 USD UNCHANGED
Last Price Updated: 5:16 PM EST, Dec 31, 2018 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about Sanofi-Aventis S.A.

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
3 Reasons to Buy Novavax Stock, and 1 Reason to Sell
Last year's stock market star is getting ready for its big moment -- or, has it already happened? 
Tags PFE AZN NVAX
From Motley Fool
The Biggest Drug Competition in 2021 (Hint: It Isn't COVID Vaccines)
Investors should take notice of this four-way competition. 
Tags LLY INCY REGN
From Motley Fool
Why Novavax Could Become a Latecomer Leader in the COVID Vaccine Race
This small biotech could be like the tortoise in Aesop's famous fable. 
Tags SNY NVAX Market News
From Motley Fool
‘Manufacturers and middlemen have created a vicious cycle of price increases’: Mark Cuban pledges to sell this $225 medication for $20
Americans pay $1,397 a year on average for prescription drugs and medical costs compared to $884 for Canadians. 
Tags IT:SANF AMZN LLY
From MarketWatch
Is Novavax's Growth Story Over?
The next few weeks could be critical for the biotech's coronavirus vaccine prospects. 
Tags PFE NVAX Market News
From Motley Fool
Why Lexicon Pharmaceuticals Stock Doubled and Then Some on Thursday
The FDA delivered a powerful shot of good news to the company. 
Tags Market News LXRX SNY
From Motley Fool
Is Regeneron Stock Heading to $590?
Rapid expansion beyond the Eylea franchise is causing analysts to raise their ratings on the big biotech. 
Tags REGN SNY Market News
From Motley Fool
Sanofi Spins Off an Industry-Leading Business
After divesting its active pharmaceutical ingredient segment, the slimmed-down company will have more time to focus on developing new blockbuster drugs. 
Tags Market News REGN SNY
From Motley Fool
Biond Biologics and Sanofi Enter into Global Licensing Agreement for BND-22, a Novel Immune Checkpoint Inhibitor Targeting the ILT2 Receptor
Biond to receive $125 million upfront with more than $1 billion in potential development, regulatory, and sales milestones plus royalty payments 
From PR Newswire
3 Coronavirus Stocks to Stay Miles Away From in 2021
Their coronavirus projects fell behind, faltered, or failed. 
Tags SNY MRNA PFE
From Motley Fool
Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines
Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines 
From Business Wire News Releases
Up 1,530% in 2020, Is Vaxart Still a Buy?
The biotech stock could still have big gains ahead, and not just because of its COVID-19 vaccine candidate. 
Tags Market News VXRT SNY
From Motley Fool
What's Next
Today I got a promotional mail reading” “What's next?” -- particularly appropriate today after yesterday's events disarray including the still buoyant stock market. 
Tags Stocks / Equities
From Blogs - TalkMarkets
Moderna Hires Amgen Executive As Chief Commercial Officer To Bolster Vaccine Marketing
Moderna Inc (NASDAQ: MRNA), which received the fourth regulatory nod for its investigational coronavirus vaccine with the conditional ... 
Tags Biotech AMGN RHHBY
From Benzinga
Corinne Le Goff, Pharm.D. Will Join Moderna as Chief Commercial Officer on January 19
Corinne Le Goff, Pharm.D. will join Moderna as Chief Commercial Officer on January 19. 
From Business Wire News Releases
A Specialty Consolidator: Biopharma Aytu Looks To Acquisitions And Licensing To Propel Growth Through 2021
The following article is sponsored by the clinical communications unit of Redington, Inc. The information contained in this article in ... 
Tags AYTU AMPE Benzinga
From Benzinga
3 Recession-Proof Healthcare Stocks to Buy for 2021
These stocks can handle whatever the new year has in store. 
Tags DXCM RHHBY VRTX
From Motley Fool
Market Briefing For Tuesday, Jan. 5
A stiff hangover greeted the big-cap market to start the year, while relative stability or rebounds were seen in a number of small-cap stocks that struggled late in 2020. Reinforcing my suspicion about... 
Tags Stocks / Equities Pharma/Biotech Technology
From Blogs - TalkMarkets
The Worst Mistake Novavax Investors Can Make Right Now
Investors will soon have data to judge management's big projections. 
Tags PFE SNY NVAX
From Motley Fool
3 Top Biotech Buyout Candidates in 2021
Big drugmakers could be attracted to these smaller players with promising pipelines. 
Tags BNTX EDIT PFE
From Motley Fool
5 Big ETF Stories Of 2020 Worth Watching In 2021
After slipping into a bear market in late March, Wall Street made an astounding rebound with major indices soaring to historic highs. This is especially true against the backdrop of super-easy monetary... 
Tags Stocks / Equities ETFs
From Blogs - TalkMarkets
Week In Review: How Trump's Policies Moved Stocks -Saturday, Dec. 26
Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump and his administration with this weekly... 
Tags Pharma/Biotech Stocks / Equities Energy
From Blogs - TalkMarkets
Here's What Investors Need to Know About Sanofi and GlaxoSmithKline's COVID Vaccine Setback
Hopefully, the backup plan works. 
Tags Market News SNY GSK
From Motley Fool
Better Coronavirus Stock: Pfizer vs. BioNTech
One healthcare company is confident about its future while the other tries to recapture its former glory. 
Tags BAYR/Y LLY REGN
From Motley Fool
Where Will Novavax Be in 1 Year?
Investors cheered for Novavax's science this year. Next year, they'll cheer for its revenue. 
Tags SNY Market News NVAX
From Motley Fool
FDA Refuses to Approve Novartis' $9.7 Billion Cholesterol Drug for Now
The FDA's inability to inspect an overseas manufacturing facility is holding up an application for inclisiran. 
Tags NVS ALNY AMGN
From Motley Fool
2 Reasons It's Not Too Late to Buy BioNTech
The German biotech, which just went public last year, is a member of a coronavirus vaccine dream team. 
Tags BNTX PFE Market News
From Motley Fool
Why AstraZeneca's and Sanofi's Bad News Could Be Great News for Pfizer and Moderna
The challenges for two big drugmakers could translate to opportunities for their rivals in the COVID-19 vaccine race. 
Tags Market News MRNA GSK
From Motley Fool
Dr. Fauci says Biden and Harris should receive COVID-19 vaccination ‘as soon as we possibly can’
Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases, said, ‘You still want to protect people who are very important to our country right now.’ 
Tags MRNA Personal Finance COMP
From MarketWatch
Could Regeneron Pharmaceuticals Be a Millionaire-Maker Stock?
A winning culture and proven science should make this stock a winner. 
Tags REGN SNY Market News
From Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback